Literature DB >> 31002431

External Validation of a Pretransplant Biomarker Model (REVERSE) Predictive of Renal Recovery After Liver Transplantation.

Josh Levitsky1, Sumeet K Asrani2, Michael Abecassis3, Richard Ruiz2, Linda W Jennings2, Goran Klintmalm2.   

Abstract

In patients with end-stage liver disease, the ability to predict recovery of renal function following liver transplantation (LT) remains elusive. However, several important clinical decisions depend on whether renal dysfunction is recoverable after LT. We used a cohort of patients undergoing LT to independently validate a published pre-LT model predictive of post-transplant renal recovery (Renal Recovery Assessment at Liver Transplant [REVERSE]: high osteopontin [OPN] and tissue inhibitor of metalloproteinases-1 [TIMP-1] levels, age < 57, no diabetes). Serum samples pre-LT and 4-12 weeks post-LT (n = 117) were analyzed for kidney injury proteins from three groups of recipients: (1) estimated glomerular filtration rate (eGFR) < 30 mL/minute/1.73 m2 prior to and after LT (irreversible acute kidney injury [AKI]), (2) eGFR < 30 mL/minute/1.73 m2 prior to LT and >50 mL/minute/1.73 m2 after LT (reversible AKI [rAKI]) (3) eGFR > 50 mL/minute/1.73 m2 prior to and after LT (no AKI). In patients with elevated pre-LT serum levels of OPN and TIMP-1, recovery of renal function correlated with decreases in the level of both proteins. At 4 weeks post-LT (n = 77 subset), the largest decline in OPN and TIMP-1 was seen in the rAKI group. Validation of the REVERSE model in this independent data set had high area under the curve (0.78) in predicting full post-LT renal recovery (sensitivity 0.86, specificity 0.6, positive predictive value 0.81, negative predictive value 0.69). Our eGFR findings were confirmed using measured GFR.
Conclusion: The REVERSE model, derived from an initial training set combining plasma biomarkers and clinical characteristics, demonstrated excellent external validation performance characteristics in an independent patient cohort using serum samples. Among patients with kidney injury pre-LT, the predictive ability of this model may prove beneficial in clinical decision-making both prior to and following transplantation.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31002431     DOI: 10.1002/hep.30667

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  4 in total

1.  Cell therapy can enable minimization of immunosuppression.

Authors:  James M Mathew; Joseph R Leventhal
Journal:  Nat Rev Nephrol       Date:  2020-09       Impact factor: 28.314

2.  Is Prioritization of Kidney Allografts to Combined Liver-Kidney Recipients Appropriate? PRO.

Authors:  Tiffany T Truong; Mitra K Nadim
Journal:  Kidney360       Date:  2021-10-15

3.  Discovery and Validation of a Biomarker Model (PRESERVE) Predictive of Renal Outcomes After Liver Transplantation.

Authors:  Josh Levitsky; Sumeet K Asrani; Goran Klintmalm; Thomas Schiano; Adyr Moss; Kenneth Chavin; Charles Miller; Kexin Guo; Lihui Zhao; Linda W Jennings; Merideth Brown; Brian Armstrong; Michael Abecassis
Journal:  Hepatology       Date:  2020-01-28       Impact factor: 17.425

4.  Discovery and validation of a novel blood-based molecular biomarker of rejection following liver transplantation.

Authors:  Josh Levitsky; Sumeet K Asrani; Thomas Schiano; Adyr Moss; Kenneth Chavin; Charles Miller; Kexin Guo; Lihui Zhao; Manoj Kandpal; Nancy Bridges; Merideth Brown; Brian Armstrong; Sunil Kurian; Anthony J Demetris; Michael Abecassis
Journal:  Am J Transplant       Date:  2020-05-25       Impact factor: 8.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.